基于CLSI易感剂量依赖类别的daptomycin使用的药监测分析
Ming M Zhang1, Ryan W Stevens1, Jennifer L Adema2
1Department of Pharmacy, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Infectious diseases and therapy
|September 26, 2023
概括
高剂量达普托米辛 (≥7.5毫克/公斤) 在治疗易受感染的肠球菌感染时,与标准剂量 (≤6.5毫克/公斤) 具有可比的安全性. 这项研究发现,高达普托米辛剂量并没有增加不良事件的风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 临床药房 临床药房
背景情况:
- 对于敏感的剂量依赖的Enterococcus物种,建议使用8-12mg/kg的达普托米辛剂量.
- 与标准4-6 mg/kg剂量相比,高剂量达普托米辛的安全性数据有限.
研究的目的:
- 为了比较高剂量与标准剂量的达普托米辛在患有Enterococcus感染的患者的安全结果.
- 为了确定与达普托米辛不良反应相关的风险因素.
主要方法:
- 对119名成人患者进行了回顾性队列研究,这些患者在治疗肠球菌感染时接受了达普托素 (MIC 2-4 mg/L).
- 患者分为标准剂量 (≤6.5 mg/kg) 和高剂量 (≥7.5 mg/kg) 的两组.
- 主要安全性结果:由肌酸激酶升高,埃索诺菲利亚,埃索诺菲尔性肺炎和肝酶升高组成的组合.
主要成果:
- 中位数剂量为6.0 mg/kg (标准) 和8.1 mg/kg (高).
- 复合安全终点发生在标准剂量组的32.0%和高剂量组的32.5% (p=0.96).
- 同时使用抗组胺药物与不良事件有关,但达普托米辛剂量或他类药物的使用没有.
结论:
- 高剂量的达普托米辛与标准剂量的达普托米辛相比没有增加实验室异常或不良药物反应.
- 由于不良事件,daptomycin剂量调整很少发生 (8.1%).
相关概念视频
Antimicrobial Effectiveness
37
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
37
Pharmacovigilance
876
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
876


